EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Ceftaroline and ceftobiprole monotherapy for the treatment of Staphylococcus aureus infections: a systematic review and Bayesian meta-analysis

Emanuele Rando iD, Eugenia Magrini, Flavio Sangiorgi iD, Federica Salvati, Francesca Catania, Marta Chiuchiarelli iD, Elena Matteini, Massimo Fantoni, Carlo Torti, Luis Eduardo López-Cortés iD, Jesús Rodríguez-Baño iD, Rita Murri iD

Journal of Antimicrobial Chemotherapy · 02.07.2026 · 81 (8)

DOI: 10.1093/jac/dkag244 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 14.07.2026. Verfasst von Emanuele Rando und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cephalosporins, Staphylococcal Infections, Staphylococcus aureus. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The comparative efficacy of ceftaroline and ceftobiprole against standard of care for Staphylococcus aureus infections, including methicillin-resistant S. aureus remains uncertain. Thus, we conducted a systematic review and Bayesian meta-analysis to assess the efficacy and safety of ceftaroline and ceftobiprole monotherapy for non-urinary S. aureus infections.

Methods

We registered the protocol in PROSPERO. We searched PubMed, Embase, Scopus, and Web of Science. We included randomized controlled trials and comparative non-randomized studies reporting adjusted estimates, enrolling patients with non-urinary S. aureus infections. The primary analysis assessed clinical cure in randomized trials using a Bayesian random-effects model with a vague prior. For ceftaroline, we additionally conducted an exploratory analysis using an observationally informed prior derived from non-randomized studies with variance inflation. Risk of bias was assessed with RoB 2 and ROBINS-I and certainty of evidence with GRADE.

Results

Sixteen studies met inclusion criteria [11 ceftaroline (1030 subjects); 5 ceftobiprole (1265 subjects)]. In the primary analysis, the pooled odds ratio for clinical cure was 1.38 (95% CrI 0.81–2.44) for ceftaroline and 0.99 (95% CrI 0.59–1.62) for ceftobiprole. The exploratory ceftaroline analysis using an observationally informed prior yielded an odds ratio of 1.45 (95% CrI 0.91–2.38). Adverse events and serious adverse events were similar between groups. Certainty of evidence was low for ceftaroline and moderate for ceftobiprole.

Conclusions

Current evidence does not demonstrate superiority of ceftaroline or ceftobiprole over standard-of-care therapy for clinical cure in non-urinary S. aureus infections. Estimates remain imprecise and are largely driven by registrational trials and subgroup data. These findings support cautious, indication-specific interpretation rather than routine preference of these agents over established therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCephalosporinsStaphylococcal InfectionsStaphylococcus aureusHumansBayes TheoremCeftarolineRandomized Controlled Trials as TopicTreatment Outcome

Substanzen

Anti-Bacterial AgentsCeftarolineceftobiproleCephalosporins

Autor:innen und Institutionen

  • Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Departamento de Medicina, Facultad de Medicina, Universidad de Sevilla, Instituto de Biomedicina de Sevilla/CSIC, Sevil…
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain.
  • National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
  • Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy.
  • Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

ORCID-Profile: Emanuele Rando, Flavio Sangiorgi, Marta Chiuchiarelli, Luis Eduardo López-Cortés, Jesús Rodríguez-Baño, Rita Murri

Zitieren

APA

Rando, E., Magrini, E., Sangiorgi, F., Salvati, F., Catania, F., Chiuchiarelli, M., Matteini, E., Fantoni, M., Torti, C., López-Cortés, L. E., Rodríguez-Baño, J., & Murri, R. (2026). Ceftaroline and ceftobiprole monotherapy for the treatment of Staphylococcus aureus infections: a systematic review and Bayesian meta-analysis. Journal of Antimicrobial Chemotherapy, 81(8). https://doi.org/10.1093/jac/dkag244

Vancouver

Rando E, Magrini E, Sangiorgi F, Salvati F, Catania F, Chiuchiarelli M, et al. Ceftaroline and ceftobiprole monotherapy for the treatment of Staphylococcus aureus infections: a systematic review and Bayesian meta-analysis. Journal of Antimicrobial Chemotherapy. 2026;81(8). doi:10.1093/jac/dkag244

BibTeX
@article{Rando2026,
  author = {Rando, Emanuele and Magrini, Eugenia and Sangiorgi, Flavio and Salvati, Federica and Catania, Francesca and Chiuchiarelli, Marta and Matteini, Elena and Fantoni, Massimo and Torti, Carlo and López-Cortés, Luis Eduardo and Rodríguez-Baño, Jesús and Murri, Rita},
  title = {Ceftaroline and ceftobiprole monotherapy for the treatment of Staphylococcus aureus infections: a systematic review and Bayesian meta-analysis},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {8},
  doi = {10.1093/jac/dkag244}
}
Kostenlos starten →